One patient saw a complete response, and the therapy was well tolerated, especially compared with the adverse effects sometimes seen with chimeric antigen receptor (CAR) T-cell treatment in blood cancers thus far.
In data presented at a meeting in Boston, Massachusetts, the biotechnology company Eureka Therapeutics has reported that 3 of 6 patients with liver cancer responded to its chimeric antigen receptor (CAR) T-cell therapy, marking one of the first times that this type of treatment has succeeded in patients with solid tumors.
The statement on the proof-of-concept study of the ET140202 T-cell therapy occurred in alpha fetoprotein (AFP)—positive patients with hepatocellular carcinoma, a common form of liver cancer. The results were presented at the CAR-TCR Summit based on work being done at Xi’An Jiaotong University in China. What’s more, the 6 patients showed no observed signs of cytokine release syndrome or drug-related neurotoxicity, and 1 patient, a 52-year-old man, had a complete response. The most common side effects were fever and fatigue.
Get an Update on Research in CAR T-cell Therapy
At the data cut-off in July 2018, results involving 6 patients with pre-existing cirrhosis who have previously failed multiple lines of therapy showed the following:
“Hepatocellular carcinoma is a cancer where we have had great difficulties finding effective treatments. This study shows early but important data in the possibility of targeting solid tumors using T-cell therapy,” Yuman Fong, MD, professor of the Department of Surgery at City of Hope National Medical Center in Duarte, California, said in a statement.
The proof-of-concept study shows the potential viability of repeat dosing, combination therapy, and a higher dosing level, he said.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen